Information Provided By: 
Fly News Breaks for April 28, 2017
BSX
Apr 28, 2017 | 14:55 EDT
BofA/Merrill raised Boston Scientific's price target to $33 from $30 citing solid Q1 results and the positive Lotus update. The firm's analyst sees upside from several growth drivers including Watchman, which is now annualized at over $200M, indicating it can be a significant contributor to growth over the next several years and appears to be underappreciated by the market. BofA/Merrill rates shares a Buy.
News For BSX From the Last 2 Days
BSX
Apr 24, 2024 | 16:20 EDT
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BSX
Apr 24, 2024 | 07:03 EDT
BSX
Apr 24, 2024 | 07:01 EDT
BSX
Apr 24, 2024 | 07:00 EDT
BSX
Apr 23, 2024 | 13:18 EDT
